olaparib

October 6, 2020October 6, 2020

Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show

News

When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) prolonged the time they lived without showing signs of ... Read more

December 13, 2019December 13, 2019

NICE Recommends Lynparza Tablets for Relapsed, BRCA-mutated Advanced Ovarian Cancers

News

After an initial rejection due to cost-effectiveness concerns, the U.K.’s National Institute of Health and Care Excellence (NICE) has reversed its decision and is expanding the use of Lynparza (olaparib) tablets ... Read more

December 5, 2019December 9, 2019

China OKs Lynparza as Maintenance Therapy for Advanced Ovarian Cancers with BRCA Mutations

News

Oral Lynparza (olaparib) has been approved in China as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer who responded to initial platinum-based chemotherapy, AstraZeneca and Merck (known as MSD ... Read more

August 23, 2019October 16, 2019

Lynparza-Avastin Combo Cuts Risk of Disease Progression, Death in Advanced OC, Phase 3 Trial Shows

News

When added to Avastin (bevacizumab), Lynparza (olaparib) reduces the risk of disease progression and death in women with advanced forms of ovarian cancer who are responding to their first-line treatment with ... Read more

July 31, 2019August 26, 2019

NHS England to Cover Lynparza Earlier in Advanced OC Treatment

News

Maintenance treatment with Lynparza (olaparib) is now recommended after response to the first round of platinum-based chemotherapy in women with advanced ovarian cancer on England’s National Health Service (NHS). The decision by ... Read more

July 8, 2019

Lynparza Approved in Japan as First-Line Maintenance Therapy for Advanced OC

News

Lynparza (olaparib) has been approved in Japan as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer that is responding, partially or completely, to their initial chemotherapy, AstraZeneca and Merck (known ... Read more

June 28, 2019June 28, 2019

PARP Inhibitors Used in ‘One-two Punch’ Strategy to Kill OC Cells in Mouse Models, Study Shows

News

Researchers have developed a two-step approach that harnesses the aging process of cells, allowing breast and ovarian cancers to be effectively targeted and destroyed in cell and mouse preclinical models. ... Read more

June 19, 2019

Lynparza Approved in Europe as Initial Maintenance Therapy for Some OC

News

Women in the European Union with BRCA-mutated advanced ovarian cancer can now receive Lynparza (olaparib) as a first-line maintenance treatment, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) ... Read more

June 5, 2019June 5, 2019

Lynparza Better Than Chemo for BRCA-mutated Advanced Ovarian Cancer, Phase 3 Trial Shows

News

Lynparza (olaparib), given to advanced ovarian cancer patients with BRCA mutations who were previously treated with at least two lines of platinum chemotherapy, had significantly better response rates and progression-free survival ... Read more

May 8, 2019

Lynparza Recommended for Approval in Europe for BRCA-mutated Advanced OC

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended that Lynparza (olaparib) be approved as a first-line maintenance therapy for women with ... Read more